) has commenced a phase III randomized, placebo-controlled,
double-blind study on its cancer candidate, veliparib. The study
will evaluate the efficacy and safety of veliparib plus
carboplatin in patients suffering from early-stage,
triple-negative breast cancer.
The study, consisting of three arms, will compare veliparib
plus carboplatin or placebo plus carboplatin to standard
The key endpoint is pathological complete response which means
there should not be any evidence of residual, invasive cancer in
the breast tissue and lymph node tissue after treatment. The
secondary endpoint is the rate of eligibility for breast
conservation after treatment.
Other outcome measures that will be evaluated include
event-free survival, overall survival, and complete response
We are encouraged by AbbVie's efforts to develop the oncology
pipeline which consists of several mid and late-stage candidates.
Apart from veliparib, ABT-199 is another important late-stage
oncology candidate in AbbVie's pipeline.
We expect 2014 to be a transitional year for the company as it
absorbs the remaining impact of the genericization of its lipid
AbbVie has several pipeline-related events lined up this year
including data on multiple sclerosis candidate, daclizumab from
the DECIDE study in mid-14 and data on Elagolix from one of the
two pivotal studies in endometriosis in the second half of 2014.
Positive data on daclizumab would also allow the company to file
for approval this year.
AbbVie also has some hepatitis C virus related milestones this
year including regulatory submissions in the second quarter of
AbbVie is a Zacks Rank #3 (Hold) stock. Some better-ranked
stocks in the broader sector include
). While Actelion and Medivation carry a Zacks Rank #1 (Strong
Buy), Allergan is a Zacks Rank #2 (Buy) stock.
ABBVIE INC (ABBV): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
MEDIVATION INC (MDVN): Free Stock Analysis
To read this article on Zacks.com click here.